These findings highlight the dual role of saroglitazar in reducing hypertriglyceridemia and enhancing insulin sensitivity along with β-cell function by reduction in gluco-lipotoxicity via PPARγ agonism, garnering interest in its use for MASLD and related metabolic conditions [28]. The gene discussed is PPARG; the disease is hypertriglyceridemia.